ORIGINAL PAPERS: Therapeutic aspectsLong-term chronic baroreflex activation persistent efficacy in patients with heart failure and reduced ejection fractionGronda, Edoardoa; Seravalle, Ginob; Trevano, Fosca Quartic; Costantino, Giuseppea; Casini, Andreaa; Alsheraei, Alia; Lovett, Eric G.d; Vanoli, Emilioa,f; Mancia, Giuseppeb,e; Grassi, Guidoa,eAuthor Information aCardiovascular Department, IRCCS MultiMedica, Sesto San Giovanni bIstituto Scientifico IRCCS Auxologico cClinica Medica, Dipartimento di Scienze della Salute, Università Milano-Bicocca, Milan, Italy dCVRx, Inc., Minneapolis, Minnesota, USA eUniversità Milano-Bicocca, Milan fDepartment of Molecular Medicine, University of Pavia, Pavia, Italy Correspondence to Edoardo Gronda, MD, IRCCS MultiMedica, Sesto San Giovanni, Via Milanese 300, Milano 20141, Italy. Tel: +39 0224209460; fax: +39 0224209051; e-mail: [email protected] Abbreviations: BAT, baroreflex activation therapy; BNP, B-type natriuretic peptide; BP, blood pressure; BRS, baroreflex sensitivity; eGFR, estimated glomerular filtration rate; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; MSNA, muscle sympathetic nerve activity; NYHA, New York Heart Association Received 20 October, 2014 Revised 18 March, 2015 Accepted 18 March, 2015 Journal of Hypertension: August 2015 - Volume 33 - Issue 8 - p 1704-1708 doi: 10.1097/HJH.0000000000000603 Buy Metrics Abstract Aims: Baroreflex activation therapy (BAT) has recently been shown to reduce muscle sympathetic nerve activity and hospitalization rate while improving clinical variables through 6 months of therapy in patients with heart failure and reduced ejection fraction (HFrEF). The objective of the present study is to extend the information on this patient cohort over a long-term follow-up. Methods and results: Eleven patients were enrolled in the study and presented with optimized, stable medical therapy, New York Heart Association Class III HFrEF with left ventricular ejection fraction 40% or less, impaired functional capacity and no active cardiac resynchronization therapy. For the present report, muscle sympathetic nerve activity, baroreflex sensitivity data and hospitalization rate together with standard clinical data were collected at 12 and 21.5 ± 4.2 months following BAT activation. Two patients died during long-term follow-up. The remaining nine patients maintained the improvements observed at 6 months, including reduced sympathetic activity and rates of hospitalization. Conclusion: BAT provides long-term chronic reductions in sympathetic activity and utilization of hospital resources in patients with HFrEF. General clinical presentation, quality of life and functional capacity are likewise improved and maintained. The temporal association of BAT with sympathetic drive diminution and improvement in objective clinical measures suggests a cause-and-effect relationship that will be verified in future randomized controlled trials of outcome. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.